Published in Mol Cell Biol on February 01, 1999
Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol (2004) 2.01
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol (2010) 1.64
p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol (2002) 1.59
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomarkers Prev (2008) 1.51
Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. PLoS One (2015) 1.45
Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol (2009) 1.30
Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet (2009) 1.29
Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A (2007) 1.28
The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol (2011) 1.20
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin Med Insights Oncol (2010) 1.13
Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res (2010) 1.10
Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer (2008) 1.08
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res (2007) 1.08
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (2007) 1.07
Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer (2005) 1.05
Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer (2009) 1.03
Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol (2012) 1.03
Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol (2004) 1.02
Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res (2009) 1.01
CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding. Nucleic Acids Res (2007) 1.01
The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer (2005) 1.00
Genetic susceptibility to lung cancer--light at the end of the tunnel? Carcinogenesis (2013) 1.00
Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer (2002) 0.98
Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol (2009) 0.97
Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J Urol (2008) 0.97
The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction. Cell Rep (2016) 0.96
Germline mutations and polymorphisms in the origins of cancers in women. J Oncol (2010) 0.96
The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One (2012) 0.94
Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia (2004) 0.93
Assessment of changes in the BRCA2 and P53 genes in breast invasive ductal carcinoma in northeast Brazil. Biol Res (2014) 0.92
The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. Br J Cancer (2007) 0.92
Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis (2008) 0.92
Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol (2013) 0.92
A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites. Nucleic Acids Res (2002) 0.91
Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment. Br J Cancer (2008) 0.91
Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer (2010) 0.90
TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells. Aging (Albany NY) (2012) 0.90
Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res (2007) 0.89
Colorectal cancer: molecular mutations and polymorphisms. Front Oncol (2013) 0.89
p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate (2010) 0.89
The Evaluation of p53 Polymorphism at Codon 72 and Association With Breast Cancer in Iran: A Systematic Review and Meta-analysis. J Cancer Prev (2016) 0.89
Codon 72 polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over time. Eur J Hum Genet (2011) 0.89
Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol (2006) 0.88
A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control (2008) 0.88
Unique profile of ordered arrangements of repetitive elements in the C57BL/6J mouse genome implicating their functional roles. PLoS One (2012) 0.88
Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm. Clin Dev Immunol (2012) 0.87
Primary open angle glaucoma in a Caucasian population is associated with the p53 codon 72 polymorphism. Mol Vis (2009) 0.87
RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection. J Cancer Res Clin Oncol (2010) 0.86
Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol (2011) 0.86
Significant association of high-risk human papillomavirus (HPV) but not of p53 polymorphisms with oral squamous cell carcinomas in Malaysia. J Cancer Res Clin Oncol (2010) 0.86
Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet (2009) 0.86
A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism. Acta Otorhinolaryngol Ital (2012) 0.86
Dual promoters control the cell-specific expression of the human cell death-inducing DFF45-like effector B gene. Biochem J (2006) 0.85
Genetic polymorphism of p53, but not GSTP1, is association with susceptibility to esophageal cancer risk - a meta-analysis. Int J Med Sci (2010) 0.85
P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am J Hum Genet (1999) 0.85
p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer (2011) 0.85
In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer (2005) 0.85
p53 codon 72 polymorphism in patients affected with ulcerative colitis. J Gastroenterol (2007) 0.85
The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis (2010) 0.85
Smoking-gene interaction and disease development: relevance to pancreatic cancer and atherosclerosis. World J Surg (2005) 0.85
Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol (2005) 0.85
P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet (2009) 0.85
Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correlation Analysis. J Cancer Epidemiol (2008) 0.84
Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res (2014) 0.84
Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck. Cancer (2011) 0.84
A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol (2006) 0.83
Validation of dot blot hybridization and denaturing high performance liquid chromatography as reliable methods for TP53 codon 72 genotyping in molecular epidemiologic studies. BMC Genet (2010) 0.83
P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett (2005) 0.83
Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. Int J Cancer (2012) 0.82
TP53 codon 72 Gene Polymorphism Paradox in Associated with Various Carcinoma Incidences, Invasiveness and Chemotherapy Responses. Int J Biomed Sci (2008) 0.82
Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. PLoS One (2012) 0.82
Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer (2010) 0.81
The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects. Lung (2013) 0.81
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer (2008) 0.81
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol (2008) 0.81
TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis. World J Gastroenterol (2011) 0.80
Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms. Hum Genet (2009) 0.80
P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis. Tumour Biol (2013) 0.80
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J (2015) 0.80
Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis. Springerplus (2014) 0.79
Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. Haematologica (2008) 0.79
MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer. Oncotarget (2016) 0.79
Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B (2008) 0.79
Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma. Radiat Oncol (2013) 0.79
The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver. J Liver (2013) 0.79
TP53 codon 72 polymorphism and glioma risk: A meta-analysis. Oncol Lett (2011) 0.79
Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer. PLoS One (2012) 0.79
Polymorphisms in DNA repair genes and breast cancer risk in Russian population: a case-control study. Clin Exp Med (2014) 0.79
Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility. Mol Carcinog (2013) 0.79
Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population. Int J Clin Exp Pathol (2015) 0.78
Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. Mol Cancer Res (2014) 0.78
TAF6delta orchestrates an apoptotic transcriptome profile and interacts functionally with p53. BMC Mol Biol (2010) 0.78
Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Mol Genet Genomics (2012) 0.78
P53 genetic polymorphism of gastric cancer in Korea. Korean J Intern Med (2006) 0.78
The TP53 fertility network. Genet Mol Biol (2012) 0.78
The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clin Exp Immunol (2003) 0.78
Association of p53 and p21 polymorphisms with prostate cancer. Biomed Rep (2015) 0.77
Evidence for an epistatic effect between TP53 R72P and MDM2 T309G SNPs in HIV infection: a cross-sectional study in women from South Brazil. PLoS One (2014) 0.77
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (1991) 7.49
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol (1992) 6.56
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Human papillomaviruses in the pathogenesis of anogenital cancer. Virology (1991) 5.74
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell (1994) 5.25
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (1994) 4.77
p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science (1995) 3.74
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A (1994) 3.36
Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol (1987) 3.22
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62
Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature (1993) 2.61
Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A (1996) 2.30
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res (1993) 2.18
Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem (1993) 2.15
Is p53 polymorphism maintained by natural selection? Hum Hered (1994) 1.92
Inhibition of viral and cellular promoters by human wild-type p53. J Virol (1992) 1.83
The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene (1997) 1.79
Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays (1995) 1.26
The expression of biologically active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins. Nucleic Acids Res (1995) 1.15
DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene (1994) 1.07
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene (1996) 1.01
Molecular analysis of different allelic variants of wild-type human p53. Biochem Cell Biol (1993) 0.88
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J (1987) 3.81
Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J (1988) 3.81
Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol (1987) 3.22
The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene (2001) 2.77
Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci U S A (1997) 2.53
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J (1984) 2.45
Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J (1982) 2.29
Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene (1999) 2.25
Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene (2000) 2.20
Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology (1990) 2.17
Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Immunol (1994) 2.12
The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene (1999) 2.11
High-resolution characterization of herpes simplex virus type 1 transcripts encoding alkaline exonuclease and a 50,000-dalton protein tentatively identified as a capsid protein. J Virol (1983) 2.07
Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev (2000) 2.01
Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol (2000) 1.97
Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A (1999) 1.93
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem (1986) 1.91
Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J (1989) 1.84
Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene (1998) 1.78
HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene (2001) 1.78
Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J Gen Virol (1987) 1.78
Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene (1992) 1.76
The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene (1992) 1.68
Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol (1994) 1.57
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis (2001) 1.53
Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol Biochem Parasitol (1996) 1.52
The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region. J Biol Chem (1996) 1.51
Analysis of the anti-p53 antibody response in cancer patients. Cancer Res (1993) 1.49
Human papillomaviruses, cervical cancer and cell polarity. Oncogene (2008) 1.47
Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica (1999) 1.46
Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages. J Immunol (1991) 1.46
E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem (1998) 1.45
Herpes simplex virus non-structural proteins. IV. Purification of the virus-induced deoxyribonuclease and characterization of the enzyme using monoclonal antibodies. J Gen Virol (1983) 1.44
The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene (1999) 1.44
Diagnostic iodised oil embolisation of liver tumours--the Hammersmith experience. Eur J Radiol (1993) 1.38
Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine (2001) 1.37
Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J (1994) 1.37
Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis (2005) 1.32
Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol (1999) 1.32
Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania donovani lipophosphoglycan. J Immunol (1992) 1.32
The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology (1994) 1.27
General suppression of macrophage gene expression during Leishmania donovani infection. J Immunol (2001) 1.25
Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene (1994) 1.22
HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene (2007) 1.21
HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene (2000) 1.21
Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol (2001) 1.21
The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction. Oncogene (2010) 1.19
c-fos and tumor necrosis factor gene expression in Leishmania donovani-infected macrophages. Mol Cell Biol (1989) 1.19
Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J Gen Virol (1997) 1.18
Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol (1997) 1.17
The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol (1995) 1.16
Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis (1999) 1.15
The expression of biologically active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins. Nucleic Acids Res (1995) 1.15
HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene (1999) 1.12
Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene (1997) 1.11
Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene (2008) 1.10
Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J Virol (1995) 1.08
DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene (1994) 1.07
Prolactin studies in "functionless" pituitary tumours. Br Med J (1975) 1.07
Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6. Oncogene (2000) 1.05
Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and EJ-ras. Int J Cancer (1988) 1.05
Alteration of Leishmania donovani infection levels by selective impairment of macrophage signal transduction. J Immunol (1993) 1.04
Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene (1999) 1.02
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene (1996) 1.01
Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene (1993) 1.00
Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J Biol Chem (2000) 1.00
HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Oncogene (1996) 0.99
Alternative splicing of human p53 transcripts. Oncogene Res (1987) 0.97
Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res (1991) 0.97
Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. J Gen Virol (1987) 0.97
Children's ability to make probability estimates: skills revealed through application of Anderson's functional measurement methodology. Child Dev (1989) 0.94